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Abstract
Aberrant retinoid signaling in human cancers is
extending from the nucleus to the cytoplasm. Re-
cently, we have demonstrated frequent epigenetic in-
activation of a retinoic acid receptor (RAR), RARb2, in
nasopharyngeal carcinoma (NPC). To further explore
targets contributing to aberrant retinoid signaling in
NPC, the expression of cellular retinol-binding pro-
teins (CRBPs), cellular retinoic acid–binding proteins
(CRABPs), RARs, and retinoid X receptors (RXRs) was
examined. Apart from RARb2, transcriptional silencing
of two CRBPs, CRBPI and CRBPIV, was observed in
NPC cell lines and xenografts. Hypermethylation of
CRBPI and CRBPIV CpG islands was found to be
closely correlated with the loss of expression. Treat-
ment with the DNA methyltransferase inhibitor, 5-aza-
2V-deoxycytidine, resulted in reexpression of CRBPI
and CRBPIV gene expression in NPC cell lines. Both
CRBPI and CRBPIV hypermethylations were also
observed in 43/48 (87.8%) and 26/48 (54.2%) primary
NPC tumors, respectively. Here, we reported for the
first time that CRBPIV was transcriptionally inactivated
by promoter hypermethylation in human cancer.
Simultaneous methylation of CRBPI, CRBPIV, and
RARb2 was commonly found in NPC primary tumors.
Our findings implied that epigenetic disruption of the
CRBPs, CRBPI and CRBPIV, is important in NPC
tumorigenesis and may contribute to the loss of
retinoic acid responsiveness in cancer.
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Introduction
Retinol, or vitamin A, is indispensable for embryonic devel-
opment, growth, vision, and survival of vertebrates [1]. The
vitamin A metabolite, retinoic acid, regulates multiple bio-
logic processes, including cell proliferation and differentia-
tion, by modulating the rate of transcription of numerous
target genes. The effects of retinoic acid are mediated by
at least two types of proteins: cellular retinoid-binding
proteins and nuclear retinoid receptors. The cellular retinoid-
binding proteins, including CRBPs and cellular retinoic acid–
binding proteins (CRABPs), belong to a family of cytosolic
proteins binding small hydrophobic ligands [2]. CRBPs are
proposed to facilitate the formation of retinol esters for storage
or conversation of retinol to retinoic acid through a retinal inter-
mediate. These proteins may also participate in the entry of
retinol into the cell [3]. The function of CRABPs is to protect
retinoids in vivo from other cellular proteins, transform bound
retinoid into specific biologic compounds, and modulate the
concentration of free retinoic acid available to nuclear retinoid
receptors [4]. Retinoid receptors function as ligand-inducible
transcription factors. Two subtypes of retinoid receptor exist,
namely, retinoic acid receptors (RARs) and retinoid X recep-
tors (RXRs). RARs are activated by all-trans-retinoic acid, and
9-cis-retinoic acid activates both RARs and RXRs. RARs form
heterodimers with RXRs, which regulate transcription by bind-
ing at the retinoic acid response elements (RAREs) on the
promoter regions of various target genes [5].
Aberrant retinoid signaling in cancer has been firstly
highlighted by the leukemogenic role of the promyelocytic
leukemia–RARa fusion protein [6]. Frequent reduced expres-
sion and aberrant promoter methylation of RAR2 in solid
cancers have also been reported [7–10]. Aside from retinoid
receptors, transcriptional silencing of a cellular retinoid-binding
protein, CRBPI, by promoter hypermethylation is common in
human cancers [11]. In NPC, only mild growth inhibition was
observed when treating with 13-cis retinoic acid, although
retinoid was used in chemotherapy and chemoprevention of
head and neck cancer [12]. These data implied that defects in
retinoid signaling may occur in NPC. Our previous study has
demonstrated that transcription silencing of RAR2 by pro-
moter hypermethylation is common in both NPC cell lines and
primary tumors [13]. To explore targets contributing to aberrant
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retinoid signaling in NPC, we investigated the expression
of retinoid signalingmolecules (CRBPs,CRABPs,RARs, and
RXRs) comprehensively. Besides RAR2, we have firstly
discovered the silencing of two cellular retinol-binding pro-
teins (CRBPs), CRBPI and CRBPIV, by promoter hyper-
methylation in NPC cells. Our findings demonstrated that
hypermethylation of CRBPs is common in NPC and may
contribute to the disruption of retinoid signaling in this cancer.
Materials and Methods
Cell Lines, Xenografts, and Primary Tumors
Five NPC cell lines (C666-1, CNE1, CNE2, HK1, and
HONE1), three xenografts (X2117, X666, and XNPC8), an
immortalized nasopharyngeal epithelial cell line (NP69), and
two samples of normal nasopharyngeal epithelial outgrowth
cultures (NP1 and NP2) were included in our study [14,15].
The NPC cell lines were maintained in RPMI 1640 medium
supplemented with 10% FBS, whereas NP69 was grown in
keratinocyte serum-free medium (Invitrogen, Carlsbad, CA).
Forty-nine cases of archived paraffin-embedded primary
NPC tumors were retrieved from the pathology bank of
the Department of Anatomical and Cellular Pathology at
The Chinese University of Hong Kong (Hong Kong, SAR,
China). The neoplastic cells were isolated from each tumor
sample by microdissection and subjected to DNA extraction
as described previously [16]. The histologic diagnoses of
the specimens were confirmed by a pathologist. All of these
tumors were classified as undifferentiated carcinomas.
The male-to-female ratio of patients was 4.8:1. The age
range was 36 to 68 years (mean 52 years). The clinical
disease stage of patients is from stages II to IV (UICC
staging classification).
ReverseTranscriptionPolymeraseChainReaction (RT-PCR)
ThemRNAexpression ofCRBP (CRBPI,CRBPII,CRBPIII,
andCRBPIV), CRABP (CRABPI andCRABPII), RAR (RARa,
RAR2, and RARc), and RXR (RXRa, RXRb, and RXRc)
genes in NPC cell lines, xenografts, and pool samples from
normal nasopharyngeal epithelia (normal NP) was exam-
ined by RT-PCR analysis. Total RNA of nasopharyngeal
samples was isolated using TRIZOL reagent (Invitrogen)
according to the manufacturer’s protocol. Two micrograms
of total RNA from each sample was subjected to cDNA
synthesis using Superscript II reverse transcriptase (In-
vitrogen). The primers and conditions for RT-PCR analysis
were listed in Table 1. The transcript of GAPDH was am-
plified as control.
Real-Time RT-PCR
The expression of CRBPI, CRBPIV, and RAR2 was
quantitatively examined in nasopharyngeal epithelial cells
by real-time RT-PCR analysis. By using the SYBR Green
RT-PCR Kit (Applied Biosystems, Foster City, CA), PCR
products were stained with SYBR Green and analyzed using
an I-cycler (Bio-Rad, Hercules, CA). The PCR primers and
conditions were listed in Table 1. All reactions were per-
formed in triplicate. Relative mRNA of the target gene of
each NPC line was normalized with -actin and calculated
using the 2[-DDC(T)] method, which compares the mRNA
amount of each sample to that of normal NP.
Bisulfite Sequencing
To investigate the de novo methylation pattern of the 5V
CpG island of CRBPI and CRBPIV in NPC, five NPC cell
lines, three xenografts, and two normal nasopharyngeal
epithelial cell growths (NP1 and NP2) were subjected to
bisulfite sequencing. Genomic DNA were modified by bisul-
fite treatment using the CpGenome DNA Modification Kit
(Intergen, New York, NY). For the CRBPI and CRBPIV
genes, the DNA sequence of the putative promoter and exon
1 were obtained from the UCSC Genome Browser, and the
CpG islands of these genes were then identified. The criteria
of a 5V CpG island are: GC content > 60%, ratio of CpG to
GpC > 0.6, and minimum length of 200 bp. The PCR primers
are listed in Figure 2. For bisulfite sequencing, PCR ampli-
fication was performed on 100 ng of bisulfite-modified ge-
nomic DNA. The amplified fragments were cloned, and 8 to
10 clones of each sample were sequenced with a Big Dye
Terminator Reaction Mix and analyzed by a ABI 3100 Ge-
netic Analyzer (Applied Biosystems).
Methylation-Specific PCR (MSP)
The promoter methylation status of CRBPI, CRBPIV, and
RAR2 in the primary tumors was investigated by MSP as
described previously [17]. Genomic DNA of the micro-
dissected specimens were modified by bisulfite treatment.
Primer sequences for both methylated and unmethylated
alleles of the genes were shown in Figure 2. One microliter of
bisulfite-modified DNA from the samples was subjected to
PCR amplification. In vitro methylated DNA (IVD) (Intergen)
served as a control for methylated sequences, whereas
DNA from peripheral blood lymphocytes (PBLs) served as
a control for unmethylated sequences. All MSP reactions
were duplicated. Twenty-five microliters of PCR products
was loaded onto a 10% nondenaturing polyacrylamide
gel, stained with ethidium bromide, and visualized under
UV illumination.
5-Aza-2 V-deoxycytidine Treatment
To examine the correlation of promoter hypermethylation
and expression ofRAR2,CRBPI, andCRBPIV genes, NPC
cell lines were subject to 5-aza-2V-deoxycytidine treatment.
Cells were plated and incubated for 4 days with 0, 1, 3,
and 5mM 5-aza-2V-deoxycytidine (Sigma Chemical Co., St.
Louis, MO). The medium and the drug were replaced every
24 hours, and cells were harvested for total RNA and DNA
extraction after 4 days.
Results
Aberrant Expression of CRBPI, CRBPIV, CRABPI, and
RAR2 in NPC
In this study, we have comprehensively examined the
transcription of the CRBP (CRBPI, CRBPII, CRBPIII, and
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CRBPIV ), CRABP (CRABPI and CRABPII), RAR (RARa,
RAR2, and RARc) and RXR (RXRa, RXR, and RXRc)
genes in NPC cell lines, xenografts, and pool samples from
normal nasopharyngeal epithelia (normal NP) by RT-PCR
analysis. Among the 12 genes examined, CRBPII and
CRABPI showed no expression in normal nasopharyngeal
epithelial cells. The finding suggested that these two genes
are not involved in the retinoid signaling in this cell type. We
have also found the expression of seven genes (CRBPIII,
CRABPII, RARa, RARc, RXRa, RXR, and RXRc) in all NPC
samples as well as normal NP. As shown in Figure 1A,
only the expression of three retinoid signaling molecules,
including RAR2, CRBPI, and CRBPIV, was lost in most
of the NPC cell lines and xenografts. Consistent with our
previous report, expression of RAR2 was lost in 60% of
NPC cell lines (3/5; C666-1, CNE2, and HK1) and an
NPC xenograft (X666). The complete loss of RAR2
expression in these NPC samples has also been con-
firmed by real-time RT-PCR analysis. The quantitative
analysis has further demonstrated a dramatic down-
regulation of RAR2 expression in the other two NPC
cell lines, CNE1 and HONE1 (Figure 1B).
The CRBPI transcripts were found to be lost in 5/5 (100%)
NPC cell lines (C666-1, CNE1, CNE2, HK1, and HONE1)
and 2/3 xenografts (2/3; X666 and XNPC8) by both conven-
tional and quantitative RT-PCR analysis. Downregulation of
CRBPI transcript (35-fold) was also detected in the xenograft
X2117 (Figure 1B). For the CRBPIV gene, no expression
has also been detected in all NPC cell lines and 2/3 xeno-
grafts (X2117 and X666), whereas downregulation of the
gene was observed in the xenograft XNPC8 (Figure 1B).
Our results demonstrated that loss of CRBPI and CRBPIV
expression was frequently detected in NPC cell lines
and xenografts.
Methylation Status of CRBPI and CRBPIV Promoters
in NPC Cell Lines and Xenografts
Aberrant promoter hypermethylation is closely related
to the loss of gene expression of cancer-related genes in
human cancer. To assess whether the loss of CRBPI
and CRBPIV expression in NPC was correlated with
promoter hypermethylation, the methylation status of the
5V CpG island of the genes was determined by bisulfite geno-
mic sequencing.
Table 1. PCR Primer Sequences and Conditions for RT-PCR and Real-Time Quantitative RT-PCR.
Genes Sequences Product Size (bp) Annealing (jC) Cycles
RT-PCR
CRBPI Forward: 5V-AAACTGGCTCCAGTCACTCC-3V 610 65 35
Reverse: 5V-CAGGTCACTTTATTGGCATGG-3V
CRBPII Forward: 5V-CAGAATGGAACCTGGGAGAT-3V 352 60 35
Reverse: 5V-AGGTCAGCTCCAGGTACAGC-3V
CRBPIII Forward: 5V-CGGAGAGAAGCCAAGATCCC-3V 239 67 35
Reverse: 5V-TGGGACGCCAGACCTTGACC-3V
CRBPIV Forward: 5V-TCCACATCCAGCAGCAGAGCC-3V 182 67 35
Reverse: 5V-GGACAGGTTTATTGAAGCTGAGC-3V
CRABPI Forward: 5V-CCTTGCGAGCTCAGAGTGT-3V 721 62 35
Reverse: 5V-TTTGAGACACGTCTAACCAGTTT-3V
CRABPII Forward: 5V-CCAACTTCTCTGGCAACTGG-3V 400 62 35
Reverse: 5V-TAGACCCTGGTGCACACAAC-3V
RARa Forward: 5V-GTCTTTGCCTTCGCCAACCAG-3V 333 60 35
Reverse: 5V-GCCCTCTGAGTTCTCCAACA-3V
RAR2 Forward: 5V-TGCAAGGGAGATCATGTTTG-3V 1360 60 35
Reverse: 5V-TTATTGCACGAGTGGTGACTG-3V
RARc Forward: 5V-TTCGAGATGCTGAGCCCTAGCTTCC-3V 351 62 35
Reverse: 5V-CATGCCCACTTCAAAGCACTTCTGC-3V
RXRa Forward: 5V-TTCTCCACCCAGGTGAACTC-3V 805 62 35
Reverse: 5V-GGGTGAAAAGCTGTTTGTCG-3V
RXR Forward: 5V-CTTTCTCTCAGGGGCTTCCT-3V 521 62 35
Reverse: 5V-ACCCCATGGAAGAACTGATG-3V
RXRc Forward: 5V-CAGGAAAGCACTACGGGGTA-3V 798 62 35
Reverse: 5V-GCTGTTCCGGATACTTCTGC-3V
GAPDH Forward: 5V-TGAAGGTCGGAGTCAACGGATTTGGT-3V 983 65 35
Reverse: 5V-CATGTGGGCCATGAGGTCCACCAC-3V
Real- time QRT-PCR
CRBPI Forward: 5V-GGGAAGGAGTTTGAGGAGGA-3V 105 60
Reverse: 5V-TTCTCACCCTTCTGCACACA-3V
CRBPIV Forward: 5V-TCCACATCCAGCAGCAGAGCC-3V 182 65
Reverse: 5V-GGACAGGTTTATTGAAGCTGAGC-3V
CRABPI Forward: 5V-AGGTCGGAGAAGGCTTTGAG-3V 104 60
Reverse: 5V-AGAAGAGTTTGCGTGCAGTG-3V
RAR2 Forward: 5V-CAGGAGAAAGCTCTCAAAGCA-3V 117 60
Reverse: 5V-CTTGGGACGAGTTCCTCAGA-3V
-Actin Forward: 5V-CGCGAGAAGATGACCCAGAT -3V 98 60
Reverse: 5V-GTACGGCCAGAGGCGTACAG-3V
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For CRBPI gene, a 414-bp fragment from the 5V CpG
island was amplified and a total of 38 CpG dinucleotides was
investigated (Figure 2A). Dense methylation was observed
in sevenNPC samples (C666-1, CNE1, CNE2, HK1, HONE1,
X666, and XNPC8) without CRBPI expression. Partial meth-
ylation was found in a xenograft (X2117) that showed down-
regulation of CRBPI expression. No aberrant methylation
was found in the two normal nasopharyngeal epithelial sam-
ples (NP1 and NP2). For CRBPIV, 29 CpG dinucleotides
within its 5V-promoter region were investigated (Figure 2B).
The 5V CpG island of CRBPIV, especially the CpG sites
within exon 1, exclusively methylated in all seven NPC lines
(C666-1, CNE1, CNE2, HK1, HONE1, X2117, and X666)
incapable of expressing CRBPIV. No methylation was
observed in CRBPIV-expressing NPC xenograft (XNPC8)
and normal nasopharyngeal epithelial cells (NP1 and NP2).
The results suggest a strong correlation of transcriptional
silencing of CRBPI and CRBPIV with dense methylation of
their promoters.
In addition to CRBPI and CRBPIV, we also examined the
methylation pattern of RAR2 promoter as described previ-
ously [9,10,13]. Dense methylation of RAR2 promoter was
found in five NPC cell lines (C666-1, CNE1, CNE2, HK1, and
HONE1) and an NPC xenograft (X666), which showed either
absent or dramatic reduction in RAR2 expression. How-
ever, no methylation was found in XNPC8, although it
showed a reduced expression of RAR2. Methylated
sequences were rarely found inRAR2-expressing samples,
including an NPC xenograft (X2117) and normal naso-
pharyngeal epithelial outgrowths (NP1 and NP2). The find-
ings confirmed that promoter hypermethylation is the major
mechanism for RAR2 inactivation in NPC [13].
Reactivating CRBPI and CRBPIV Expression after
5-Aza-2 V-deoxycytidine Treatment
Because promoter methylation status is intimately asso-
ciated with CRBPI and CRBPIV, we sought to ask whether
demethylation of the CRBPI and CRBPIV promoters is
required for restoration of their expression. For this purpose,
we treated the NPC cell line HK1, which showed transcrip-
tional silencing and promoter hypermethylation of CRBPI
and RAR2 with the demethylation agent, 5-aza-2V-deoxy-
cytidine. After treatment, unmethylated alleles of CRBPI
and RAR2 were detected by MSP analysis, whereas re-
expression of these genes was observed. (Figure 3, A and
C). Reexpression and demethylation of the CRBPIV gene
were also detected in the 5-aza-2V-deoxycytidine–treated
NPC cell line C666-1 in which dense methylation and tran-
scriptional inactivation of CRBPIV were found (Figure 3B).
Promoter Hypermethylation of CRBPI and CRBPIV in
Primary NPC Tumors
To assess the prevalence of promoter hypermethylation
of CRBPI and CRBPIV in primary NPC tumors, we examined
49 primary NPC samples by MSP. The results of MSP
analysis showed remarkable correlation with bisulfite ge-
nomic sequencing in cell lines and xenografts. Collectively,
aberrant promoter hypermethylation of CRBPI and CRBPIV
was found in 43/49 (87.8%) and 26/48 (54.2%) of primary
Figure 1. Detection of CRBPI, CRBPIV, and RAR2 expression in NPC cell lines, xenografts, and normal nasopharyngeal epithelia (NP) by (A) RT-PCR analysis
and (B) real-time RT-PCR analysis.
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NPCs, respectively. We have correlated the methylated sta-
tus of each of the genes with the stage of the NPC patient.
No significant correlation between methylation of these
genes and stage was found (data not shown). Forty-six
samples (93.9%) showed aberrant methylation of either
CRBPI or CRBPIV. The representative examples of MSP
analysis of CRBPI and CRBPIV of NPC primary tumors are
shown in Figure 4. Among 49 primary tumors examined,
23 (46.9%) cases showed promoter hypermethylation of
both CRBPI and CRBPIV genes (Table 2). Taken together,
our results demonstrated high frequencies of CRBP pro-
moter hypermethylation in NPC cell lines, xenografts, and
primary tumors.
To elucidate the relationship of promoter hypermethyl-
ation ofCRBPI,CRBPIV, andRAR2, the methylation status
of RAR2 was also determined in the 49 primary tumors by
MSP. Hypermethylation of RAR2 was detected in 37/47
(78.7%) of primary tumors. No significant correlation of
RAR2 methylation and stage of patients was found. Similar
findings have also reported in our previous study [13].
Forty-seven primary tumors (95.9%) showed methylation
of at least one of the CRBPI, CRBPIV, and RAR2 genes
(Table 2). Promoter methylation of all three genes was
found in 1/3 xenografts, 5/5 cell lines, and 21/49 (42.9%)
primary tumors. The findings showed that the concurrent
simultaneous inactivation of the CRBPI, CRBPIV, and
RAR2 genes by hypermethylation is relatively common
in NPC.
Discussion
In the present study, we have screened for aberrant expres-
sion of the components of the retinoic acid pathway (cellular
retinoid-binding proteins and nuclear retinoid receptors) in
NPC. In addition to the well-studied RAR2 gene, two reti-
noid signaling components,CRBPI and CRBPIV, were found
to be common targets for epigenetic inactivation. A high fre-
quency of CRBPI and CRBPIV promoter hypermethylation
Figure 2. Bisulfite sequencing of the CRBPI, CRBPIV, and RAR2 5 VCpG islands in NPC cell lines, xenografts, and normal nasopharyngeal epithelial outgrowths
(NP1 and NP2). Each row represents an individual subclone. Open circles, unmethylated CpG sites; closed circles, methylated CpG sites. The nucleotide position
of CpG sites (grey bar) is indicated at the top. The primer sequences of bisulfite sequencing and MSP analysis are listed at the bottom. RARE, retinoic acid
responsive element.
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(88% and 54%, respectively) was detected in primary NPC
tumors. The findings suggest that loss of CRBPI and
CRBPIV expression is important in NPC development. Inac-
tivation of these CRBP genes may result in the loss of
cellular retinoic acid homeostasis, inability to uptake natural
retinol, and synthesis of retinoic acid.
Figure 3. (A) Reactivation of CRBPI expression in NPC cell line (HK1) treated with 5-aza-2 V-deoxycytidine. Left panel: The reexpression of CRBPI in HK1 after
5-aza-2 V-deoxycytidine treatment. Right panel: The methylation status of CRBPI promoter of HK1 cells after demethylation. MSP analysis demonstrated that the
unmethylated sequence was detected in samples treated with 5-aza-2 V-deoxycytidine. (B) Reexpression of CRBPIV and detection of unmethylated sequences in
NPC cell line C666-1 treated with 5-aza-2 V-deoxycytidine. (C) After 5-aza-2 V-deoxycytidine treatment, RAR2 transcripts and unmethylated allele was detected
in the NPC cell line HK1.
Figure 4. Representative examples of MSP analysis of CRBPI, CRBPIV, and RAR2 in primary NPC tumors. The PCR products in lane m indicate the presence
of methylated templates of the genes; the PCR products in lane u show the presence of unmethylated alleles. In vitro methylated DNA (IVD) and peripheral blood
lymphocytes (PBLs) served as methylated and unmethylated controls, respectively. H2O, negative control.
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CRBPI is the most well-known retinoid-binding protein,
and it is postulated to regulate the uptake and intracellular
fate of retinol. This protein draws retinol from the blood-
stream into cells, solubilizes retinol and retinal, and protects
cells from membranolytic retinoid action [18]. Thus, loss of
CRBPI would be expected to compromise retinol uptake,
providing a growth advantage to cancer cells. Additionally,
the absence of CRBPI may also compromise retinoic acid
synthesis through the conversion of retinol to retinyl ester or
retinoic acid [18,19]. This conversion includes several enzy-
matic reactions that probably function through recognition of
retinoid-binding proteins [20]. In breast cancer, loss of
CRBPI expression was as frequent in ductal carcinoma
in situ as in invasive lesion, suggesting that it is a relatively
early event in carcinogenesis [21]. A functional study has
shown that downregulation of CRBP blocks differentiation
and promotes the growth of SV40-transformed breast epi-
thelial cells [22]. Recently, Esteller et al. [11] have also
demonstrated that CRBPI was commonly silenced by pro-
moter hypermethylation in various human malignancies,
including lymphoma (60%), colon cancer (57%), gastric
cancer (42%), liver cancer (30%), and breast cancer
(19%). The extremely high incidence of CRBPI methylation
(87.8%) suggested that the gene may play a role in NPC
tumorigenesis though the disruption of the retinoid signal-
ing pathway.
CRBPIV is newly identified and belongs to a clearly dis-
tinct CRBP superfamily with a relatively different mode of
retinol-binding activity [23]. In this study, we have provided
the first evidence that transcription silencing of CRBPIV by
aberrant methylation is involved in the tumorigenesis of
human cancers. The CRBPIV gene was not only frequently
inactivated in NPC, our preliminary study also detected
CRBPIV promoter hypermethylation in multiple human can-
cer cell lines, including colon cancer (2/5), prostatic cancer
(2/5), and ovarian cancer (4/13) (personal observation). The
findings implied that CRBPIV is a common target for the
disruption of retinoid signaling pathway in human cancers.
However, the exact function of this retinol-binding protein is
still not known yet. To elucidate the function ofCRBPIV in NPC
tumorigenesis, depletion ofCRBPIV expression in an immor-
talized nasopharyngeal cell line NP69 by siRNA is ongoing.
In this study, we have further confirmed a high fre-
quency of RAR2 methylation in primary NPC tumors
(78.7%). Our data also demonstrated the relatively common
simultaneous inactivation of CRBPI, CRBPIV, and RAR2 in
NPC cell lines, xenografts, and primary tumors. Although the
underlying biologic significance of this observation is largely
unknown, the findings may indicate that inactivation of all
these genes—CRBPI, CRBPIV, and RAR2—is necessary
to completely abolish the retinoid signaling pathway in NPC.
Further functional studies to investigate their roles in retinoid
signaling in nasopharyngeal epithelial cells are needed. A
recent study has also reported the relatively common simul-
taneous epigenetic inactivation of CRBPI and RAR2 in
human cancers [11]. The authors proposed that CRBPI
may have a function independent of its retinol-binding ability.
Nevertheless, these findings indicated that inactivation of the
CRBPs, CRBPI and CRBPIV, as well as loss of RAR2, are
important in the development of human cancers.
Taken together, in this study, CRBPI, CRBPIV, and
RAR2 gene silencing by promoter hypermethylation was
frequently observed in NPC. The disruption of these genes in
the majority of NPC samples may explain the resistance of
retinoic acid treatment in this cancer type. Besides, RAR2,
CRBPI, and CRBPIV are novel candidate targets involving in
aberrant retinoid signaling in human cancers. Our findings
first demonstrated that epigenetic inactivation of multiple
CRBPs is involved in the tumorigenesis of NPC.
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